Showing results (391-400 of 433) with videos related to

Sort By:
Pageof 44
Plos One|August 8, 2013
Expression analysis of combinatorial genes using a bi-cistronic T2A expression system in porcine fibroblastsSunghoon Hurh, Bumrae Cho, Dong-Joo You, et al.
Kidney Research and Clinical Practice|February 19, 2016
The effect of depression and health-related quality of life on the outcome of hemodialysis patientsHee Jung Jeon, Hayne Cho Park, Ji In Park, et al.
Scientific Reports|April 3, 2020
Author Correction: Genetic Characteristics of Korean Patients with Autosomal Dominant Polycystic Kidney Disease by Targeted Exome SequencingHyunsuk Kim, Hayne Cho Park, Hyunjin Ryu, et al.
Journal of the American Chemical Society|June 15, 2022
Reinterpreting the Fate of Iridium(III) Photocatalysts─Screening a Combinatorial Library to Explore Light-Driven Side-ReactionsJoseph C Bawden, Paul S Francis, Stephen DiLuzio, et al.
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|August 16, 2023
Adaptive Nutrition Intervention Stabilizes Serum Phosphorus Levels in Hemodialysis Patients: A Multicenter Decentralized Clinical Trial Using Real-World DataMoon Kyung Chung, Do Hyoung Kim, Ji In Park, et al.
BMC Nephrology|April 18, 2014
Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney diseaseMiyeun Han, Hayne Cho Park, Hyunsuk Kim, et al.
Dalton Transactions (Cambridge, England : 2003)|December 18, 2014
Rhenium and technetium complexes that bind to amyloid-β plaquesDavid J Hayne, Andrea J North, Michelle Fodero-Tavoletti, et al.
Science (New York, N.Y.)|September 18, 2010
Global silicate mineralogy of the Moon from the Diviner lunar radiometerBenjamin T Greenhagen, Paul G Lucey, Michael B Wyatt, et al.
Journal of Korean Medical Science|June 9, 2020
Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney DiseaseHayne Cho Park, Juhee Kim, AJin Cho, et al.
European Urology Oncology|October 8, 2023
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)Andrew Weickhardt, Farshad Foroudi, Nathan Lawrentschuk, et al.
Pageof 44